DeepVerge continues to ramp up progress across business divisions

Deepverge is a vertically integrated business, collaborating technology platforms with partners in artificial intelligence, clinical research, water technologies, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

() said its Modern Water division bagged GBP2.2mln of new orders.

The orders are for newly enhanced monitoring equipment with upgraded software and are being shipped to the UK, India and China to meet customer and partner obligations for delivery in the current financial year.

The shipments include upgraded Microtox toxicity monitoring, new models of the Microtox PD range for SARS-CoV-2 and other pathogen monitoring as well as Microsaic mass spectrometer equipment to monitor forever chemicals and contaminants of emerging concern.

“Just 11 months following the Modern Water acquisition, DeepVerge is shipping 2nd generation real-time pandemic response equipment with SARS-CoV-2 detection fully integrated to meet initial customer demand after the successful demonstration of Phase III field trials,” said Gerry Brandon, the chief executive officer of DeepVerge.

DeepVerge PLC (AIM:DVRG) said it will partner with Media.Monks to accelerate the global expansion of its hyper personalised skincare brand launch Skin Trust Club (STC).

Powered by DeepVerge’s Labskin technology, STC provides what the company describes as “hyper personalised” skincare routine accessed via smartphone.

DeepVerge PLC (AIM:DVRG, FRA:4RG) said Modern Water, its environmental division, will be the leading sponsor at the Reuters IMPACT virtual global conference on climate change on 4-7 October 2021.

Gerard Brandon, chief executive of DeepVerge, will also host a panel to discuss ‘What’s our water trying to tell us, a global perspective’.

DeepVerge PLC (LON:DVRG) could get a significant upgrade on the current target price if Microtox BT receives full clinical validation followed by a CE marking, broker Turner Pope said today.

Earlier, DeepVerge reported initial results from phase III clinical studies of the rapid Coronavirus (COVID-19) breath test showed it can deliver results in under 60 seconds.

Chief executive Gerard Brandon described the early data from the real-world assessment of the Microtox BT system as a “major milestone”.

() () Gerry Brandon talks to Proactive London’s Katie Pilbeam about the progression achieved at their Modern Water division, securing GBP2.2mln of new orders.

These orders are for the newly enhanced monitoring equipment with upgraded software and are being shipped to the UK, India and China to meet customer and partner obligations for delivery in the current financial year.

The shipments include upgraded Microtox toxicity monitoring, new models of the Microtox PD range for SARS-CoV-2 and other pathogen monitoring as well as Microsaic mass spectrometer equipment to monitor forever chemicals and contaminants of emerging concern.